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Abstract
Background: The incorporation of biological knowledge can enhance the analysis of biomedical
data. We present a novel method that uses a proteomic knowledge base to enhance the
performance of a rule-learning algorithm in identifying putative biomarkers of disease from high-
dimensional proteomic mass spectral data. In particular, we use the Empirical Proteomics Ontology
Knowledge Base (EPO-KB) that contains previously identified and validated proteomic biomarkers
to select m/zs in a proteomic dataset prior to analysis to increase performance.
Results: We show that using EPO-KB as a pre-processing method, specifically selecting all
biomarkers found only in the biofluid of the proteomic dataset, reduces the dimensionality by 95%
and provides a statistically significantly greater increase in performance over no variable selection
and random variable selection.
Conclusion: Knowledge-based variable selection even with a sparsely-populated resource such
as the EPO-KB increases overall performance of rule-learning for disease classification from high-
dimensional proteomic mass spectra.
Background
While biological knowledge is typically used to validate
the results obtained from the analysis of high-dimen-
sional biomedical data, increasingly, it is being incorpo-
rated into the statistical analysis and modeling of such
data. For example, the use of knowledge bases to help
process and analyze biomedical data for markers of
disease has been shown to produce better results than
analyzing such data in isolation [1,2]. Biomedical
knowledge bases have been growing in number and
coverage; examples of such knowledge bases include
Gene Ontology (GO), KEGG, UniProt, and EPO-KB
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Open Access[3-6]. These knowledge bases attempt to organize current
knowledge in a machine-parsable and human-under-
standable form and provide biological knowledge that
can be used when inducing models from biomedical
data.
We focus here on the analyses of proteomic data
obtained from mass spectrometry studies to uncover
putative biomarkers of disease. Typically, data mining
algorithms are used to analyze mass spectral data to
identify mass-to-charge ratios (m/zs) that are associated
with disease [7,8]. Such analyses involve sorting through
thousands of m/zs that may or may not have biological
significance [9]. There has been prior work in the use
biological knowledge to assist in proteomic biomarker
identification; typically such knowledge has been used
for post-processing m/zs that have been identified by
data mining algorithms. Barbarini, et al. used the data in
the Human Plasma Proteome Project (Hupo-PPP) to
assign putative identification to m/zs by translating the
m/z to a molecular weight in Daltons [10]. Their main
goal was in-silico identification for biomarker discovery
using a feature selection algorithm. They suggest that
performing a biologically-driven feature selection could
be beneficial.
In this paper, we present a novel method that uses a
proteomic knowledge base to enhance the performance
of a rule-learning algorithm in identifying putative
biomarkers in high-dimensional proteomic data. In
particular, we use the Empirical Proteomics Ontology
Knowledge Base (EPO-KB) that contains previously
identified and validated biomarkers to select m/zsi na
proteomic dataset and show that this knowledge-based
selection of m/zs improves the performance of the rule-
learning algorithm.
Methods
We describe two strategies for knowledge-based biomar-
ker selection in an Amyotrophic Lateral Sclerosis
proteomic dataset and evaluate the performance of
these strategies on a rule learning algorithm relative to
t h eb a s e l i n ew i t ht on ov a r i a b l es e l e c t i o n .F i g u r e1s h o w s
a flowchart of the experimental protocol. In the
following sections, we first briefly describe the proteomic
dataset and the EPO-KB and then describe the variable
selection methods, the rule learning algorithm and the
evaluation measures.
Proteomic dataset
We used a proteomic dataset from a study of a rapidly
neurodegenerative disease called Amyotrophic Lateral
Sclerosis (ALS) where the analyzed samples were
obtained from the cerebrospinal fluid (CSF) as described
in Ranganathan, et al. [7] The mass spectra from the
samples were acquired on a Ciphergen PBSIIc Biomarker
Discovery System that performs Surface Enhanced Laser/
Desorption Ionization – Time of Flight (SELDI-TOF)
mass spectrometry analysis. The dataset has 36,778 m/zs
at which relative intensities or peaks were measured in a
total of 52 samples of which 23 were cases that were
obtained from patients diagnosed with ALS and the
remaining 29 were controls that were obtained from
individuals without ALS.
The Empirical Proteomics Ontology
Knowledge Base (EPO-KB)
A biomarker can be defined as an m/z with relative
intensity within a specified interval that is associated
with a normal biologic process, a pathogenic process, or
a pharmacologic response [11]. We have developed a
knowledge base called the Empirical Proteomics Ontol-
ogy Knowledge Base (EPO-KB) that contains biomar-
kers linked to proteins, peptides and their known
modifications as well as associated diseases that we
have curated from the literature [6]. In EPO-KB, each
protein or peptide is associated with a range of m/z
values. This is due to the fact that a protein can have
Figure 1
The methodology for the knowledge-based variable
selection showing the three dataset generated.T h e
three datasets selected by None, DS variable selection, BS
variable selection were all subjected to the same rule
learning process.
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on the specific post-translational modifications, the
specific biofluid (such as CSF, plasma, nipple
aspirate fluid, or tissue lysate) from which it is obtained
and the specific method for acquiring the mass spectra
(e.g., SELDI-TOF, MALDI-TOF). An example of a
biomarker in the EPO-KB is Transthyretin. Transthyretin
is associated with the ranges 13727–13766 m/z (the
singly charged state), 6860–6685 m/z (the doubly
charged state), and 13873–13923 m/z (a post-transla-
tional modification). Given an m/z value from an
experimental spectrum, EPO-KB associates with it
proteins and peptides whose ranges of m/z values
found in the literature include this value. For the
experiments described in this paper, we removed those
biomarker entries from EPO-KB that were obtained
from Ranganathan, et al. [7] so that our analyses
simulates using a knowledge base that does not
contain knowledge extracted from the dataset being
analyzed.
Variable selection using EPO-KB
We generated three datasets each with different sets of
variables. The first dataset included all the variables from
the original ALS dataset which we call ‘None’ for no
knowledge-based variable selection. Variables for the
second and third datasets were selected in conjunction
with EPO-KB. The second dataset included only those
variables that were associated with CSF proteins and
peptides linked with neurological diseases in EPO-KB
(20 proteins and isoforms). The neurological diseases
represented in EPO-KB currently include ALS, Alzhei-
mer’s disease, and Parkinson’s disease and consist of 20
proteins and isoforms that were extracted from four
research articles. Thus, the second dataset contained
variables that were selected based on their previously
being identified in neurological diseases. The third
dataset included only those variables that were asso-
ciated with biomarkers found in CSF in EPO-KB. The
biofluids represented in EPO-KB currently include
plasma, serum, CSF, urine, and amniotic fluid; the CSF
biomarkers include 50 proteins and isoforms that were
extracted from seven research articles. Thus, the third
dataset contained variables that were selected based on
their previously being identified in the same biofluid as
found in the ALS dataset. We call the three variable
selection methods as no variable selection (None),
disease-specific variable selection (DSVS), and biofluid-
specific variable selection (BSVS).
Rule learning
Rule-learning is a useful technique for knowledge
discovery from data that is discrete [12-14]. This
technique generates a set of propositional IF-THEN
rules where a rule consists of an antecedent on its left
hand side and a consequent on its right hand side. An
example of a rule is:
IF (6889m/z =[ 0 . 2 5 –0.40]) AND (12282m/z =[ 0 . 5 0 –
0.65]) THEN (ALS = True),
where the values in square brackets represent an interval
of relative intensity for the particular m/z value. In the
above rule, the antecedent consists of two conjuncts,
each expressed as a variable-value pair. The first variable-
value pair states that the variable 6889 m/z should have
a relative intensity value that lies in the range 0.25 to
0.40. The consequent represents the value of the target
variable. For a rule derived from proteomic data, the
variables in the antecedent represent a potential panel of
biomarkers that are discriminative for the target disease
[7,8].
We used an algorithm called Rule Learner (RL) for
learning sets of IF-THEN rules from the three datasets
described in the previous section. The rules learned by RL
do not partition the input space as, for example, is done
by the classification and regression tree (CART) algo-
rithms; instead they cover overlapping regions in the
input space. RL has been used in multiple domains
including in novel biomarker discovery, and in para-
meter learning for protein crystallization [15] and is
considered to be an algorithm with low bias and
variance [16]. We chose RL for our experiments since it
was originally used by Ranganathan et al [7] to analyze
the ALS dataset. In our experiments, we constrained RL
to learn rules with a maximum of 7 variables in the
antecedents to reduce search time and space.
Since RL cannot utilize continuous variables, we
discretized the variables using the MDLPC discretization
method developed by Fayyad and Irani [17]. This
method is widely used for discretization and has been
shown to perform well on biomedical datasets [18]. In
addition to transforming a continuous variable into a
discrete one, the process of discretization also performs
variable (feature) selection, since variables that are
discretized to a single interval are not predictive of the
target variable and are ignored by the rule learning
algorithm.
Measures of performance and statistical analysis
We used balanced accuracy and Relative Classifier
Information [19] to measure the classification perfor-
mance of RL. Balanced accuracy (BACC) is superior to
accuracy since it compensates for skewed distribution of
classes in a dataset. Balanced accuracy is defined as
follows:
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where |C| is the cardinality of the target variable and
Sensitivity(c) (Specificity(c)) refers to the sensitivity
(specificity) of the target value c versus all other values
of the target. TP(c|c) (True Positives) is the number of
samples predicted to have the value c for the target
variable given that the observed value is c,F N (¬c|c) (False
Negatives) is the number of samples predicted to have a
value other than c for the target variable given that the
observed value is c,T N (¬c|¬c) (True Negatives) is the
number of samples predicted to have a value other than c
for the target variable given that the observed value is not
c,a n dF P (c|¬c) (False Postives) is the number of samples
predicted to have the value c for the target variable given
that the observed value is not c.
Relative Classifier Information (RCI) is an entropy-based
performance measure that quantifies how much the
uncertainty of a decision problem is reduced by a
classifier relative to classifying using only the prior
probability distribution of the values of the target
variable uninformed by any predictor variable [19].
T h em i n i m u mv a l u ef o rR C Ii s0 %t h a ti sa c h i e v e dw h e n
the prediction is always the majority value of the target
variable, and the maximum value is 100% that is
achieved when the value of the target variable is always
correctly predicted. RCI is sensitive to the distribution of
the target-values in the dataset and thus compensates for
the observation that it is easier to obtain high accuracies
on highly skewed datasets.
For comparing the performance of RL on the three variable
selection methods, we used the Wilcoxon paired samples
signed rank test and the paired samples t-test. The
Wilcoxon paired samples signed rank test is a non-
parametric procedure that tests whether there is sufficient
evidence that the median of two probability distributions
differ. The paired samples t-test is a parametric procedure
used to determine whether there is a significant difference
between the average values for two different sets of
samples. The test assumes that the paired differences are
independent and identically normally distributed.
Experiments
To evaluate the performance of RL on a dataset, we
performed 10 runs of 10-fold cross-validation to generate
a total of 100 folds. We computed the BACC for each fold
and averaged over the 100 folds; we report the average
BACC in the results. We computed the average RCI in a
similar fashion. For the datasets derived using DSVS and
BSVS, the BACCand RCI werevalidated usinga randomiza-
tion test. The randomization test consists of selecting
randomly the same number of variables from the original
datasets as selected by DSVS (or BSVS), applying RL to the
dataset generated using the randomly selected variables,
and evaluating its performance in terms of BACC and RCI
using 10 runs of 10-fold cross-validation. To perform the
randomizationtest,wegenerated1000datasetsbyapplying
random variable selection using the cardinality for each of
the DSVS and BSVS methods. In all experiments including
the randomization experiments, we utilized the same
training and test folds for every dataset. Thus, each of the
100 folds consisted of the same samples (though different
sets of variables), irrespective of the variable selection
method that was employed.
We also tabulated and compared the m/zst h a tw e r e
included in the antecedents of the rules learned by RL on
each of the three datasets. For this analysis, we examined
the rules generated by applying RL to the entire dataset
containing all the samples.
Results
For both DSVS and BSVS, we have to correlate the
protein to a m/z range. Utilizing the EPO-KB, we were
able to retrieve empirically generated m/z ranges (e.g.,
13593–13680), and we also included possible double
charges when selecting the variables. The original ALS
dataset contained 36,778 variables. With the DSVS, we
generated 23 ranges (46 with double charges) translating
to 1064 m/zs selected (3% of the original dataset). For
BSVS, since there was an increase in the number of
proteins (32 proteins), we generated 64 m/z ranges
including which lead to a total of 1852 m/zss e l e c t e d( 5 %
of the original dataset). Of note, all of the variables
selected by DSVS were also selected by BSVS.
The average BACCs for the different variable selection
methods are given in Table 1. The lowest average BACC
was on the dataset with no filtering (None). DSVS
resulted in an increase in average BACC with associated
decrease in sensitivity and increase in specificity over
None. BSVS resulted in the highest average BACC with
associated increase in sensitivity and no decrease in
specificity over None. The increase in average BACC
achieved by both methods of knowledge-based filtering
of variables over no filtering was statistically significant
at the 0.05 level (Table 2).
The average RCI for the various variable selection
methods are given in Table 3. The lowest average RCI
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a n dB S V Sr e s u l t e di nh i g h e ra v e r a g eR C It h a nN o n e ;t h e
increase associated with DSVS was not statistically
significant at the 0.05 level. The highest average RCI
was obtained by the BSVS method, which was statisti-
cally significant at the 0.05 level (Table 2).
O nt h er a n d o m i z a t i o nt e s t ,p e r f o r m a n c eo fD S V Sa s
measured by BACC and RCI was statisitically significant
at the 0.10 level and the performance of BSVS on both
BACC and RCI was statisitically significant at the 0.10
level (Tables 1 and 3).
The number of variables and the m/zs present in the
antecedents of the rules learned by RL on the entire
dataset for the three variable selection methods are
shown in Figure 2. Many more variables were obtained
by BSVS as compared to DSVS, and all the m/zso b t a i n e d
by BSVS were also obtained by DSVS. Also, the rules
produced by the None method had shorter antecedents
( i . e . ,f e w e rv a r i a b l e s )t h a ne i t h e rB S V So rD S V S( d a t an o t
shown).
Table 4 compares the m/zs obtained by the three
variables selection methods. Fifty percent of the variables
obtained by None were different when compared to
t h o s eo b t a i n e db yB S V S ,a n dD S V Ss e l e c t e dn on e w
variables when compared to those obtained by BSVS.
Discussion
Proteomic datasets derived from mass spectrometry
experiments are typically high-dimensional, noisy, and
have small sample sizes. The incorporation of prior
biological knowledge can help in statistical analysis and
modelingof such datasets where the goal is to identify
putative panels of biomarkers associated with disease.
We used a database of previously validated biomarkers
to perform knowledge-based variable selection to reduce
the dimensionality of a proteomic dataset associated
with ALS. Our results show that such knowledge-based
variable selection can improve the performance of a rule
learning algorithm for identifying biomarker panels. We
used the m/z ranges derived from prior published
Table 1: Average balanced accuracy (BACC) of the three variable
selection methods
Variable selection
method
BACC (± std. dev)
(Sensitivity, Specificity)
P-Value
(randomization test)
None 66.40% (± 19.66)
(53.3%, 79.5%)
-
DSVS 71.84% (± 17.49)
(50.58%, 93.1%)
0.068
BSVS 78.24% (± 18.48)
(66.78%, 89.7%)
0.003
None indicates no variable selection, DSVS is disease-specific variable
selection and BSVS is biofluid-specific variable selection.
Table 2: Statistical comparison of the three variable selection
methods using the Wilcoxon Signed Rank test and the t-test on
BACC and RCI
Methods BACC RCI
Wilcox t-test Wilcox t-text
None vs. DSVS 0.011 + 0.008 + 0.074 + 0.065 +
None vs. BSVS <0.001 + <0.001 + 0.005 + <0.001 +
DSVS vs. BSVS < 0.001 + < 0.001 + 0.007 + 0.013 +
p-values below the 0.05 significance level are in bold font. A + favors the
second method in a pair.
Table 3: Average RCI performance of the three variable selection
methods
Variable selection method RCI
(std. dev.)
P-Value
(randomization test)
None 12.72
(± 2.0)
-
DSVS 15.88
(± 4.3)
0.077
BSVS 20.15
(± 4.3)
0.001
Figure 2
Venn diagram showing the overlap of the variables
selected by RL for the three different variable
selection methods.
Table 4: m/zs that were present in the rules for None and DSVS
respectively that were not present in the rules for BSVS
Variable selection method M/zs in rules (kDa) Percent Different
None 5.58, 9.56, 10.53, 18.69 50%
DSVS None 0%
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a proteomic dataset using two strategies. First, we used
a disease-specific strategy, in which we filtered the m/zs
based on validated biomarkers associated with neurolo-
gical diseases; this resulted in increased BACC that was
statistically significant at the 5% significance level.
Second, we used a biofluid-specific strategy, in which
we filtered the m/zsb yp r o t e i n st h a tw e r ep r e s e n ti nt h e
CSF; this resulted in increased BACC and RCI that was
statistically significant at the 5% significance level. Our
approach is similar to the that used in [10] except that
instead of using a theoretical database for post-proces-
sing, we used an empirical database for preprocessing.
We did not use a database like UniProt or Hupo-PPP that
contains m/zs that are theoretically predicted for proteins
and peptides for several reasons. First, the theoretical m/z
is often not predictive of the experimentally derived m/z,
particularly for those proteins that fragment, cleave, or
undergo post-translational modifications. Second, the
same protein obtained from different biofluids differs
slightly leading to different m/zs. Using a database like
EPO-KB that contains empirically derived m/zs allows us
to use m/zs that have been recorded in previous
experiments, which are more reliable than theoretically
derived m/zs.
One limitation of our study is due to the limited data
present in the EPO-KB. Thus, the number of variables
selected by DSVS was more than 50% fewer than the
number of variables selected by BSVS. In addition, the
variables selected by DSVS was a subset of the variables
selected by BSVS. The paucity of variables available for
DSVS likely resulted in its performance being poorer
compared to that of BSVS as well as on the randomiza-
tion test. In future experiments, it would be interesting to
examine if the “intersection” of the knowledge-based
biomarker sets provide higher accuracy than the indivi-
dual biomarker sets. In our current study, since the BSVS
set is completely contained in the DSVS set, there is no
advantage in using the “intersection” of the two variables
sets. Another limitation of our study is that we did not
examine the performance of other methods for learning
predictive models in addition to the RL algorithm.
Regardless of how one selects m/zsf o rap u t a t i v e
biomarker panel, the m/zsh a v et ob ei d e n t i f i e d
definitively with techniques such as peptide mass-
fingerprinting or tandem mass spectral analyses. A
resource like EPO-KB that contains experimentally
verified m/z to protein associations, is valuable for
assigning a small list of putative proteins to m/zso f
interest in an experiment. While EPO-KB was originally
developed for this purpose, this paper demonstrates an
additional application of the knowledge in EPO-KB for
biomarker analysis of mass spectral data.
Conclusion
In conclusion, we have presented an example of how
even a sparsely-populated knowledge base such as the
EPO-KB can be used to perform variable selection to
increase classification performance on a high-dimen-
sional proteomic dataset. As more information is added
to the EPO-KB, it is expected that such knowledge-based
variable selection methods would lead to more useful
models. In the future, we will evaluate the combination
of knowledge-based biomarkers with dataset specific
markers for disease classification.
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